Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
US-2017275252-A1 · Sep 28, 2017 · US
Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
US10774047B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10774047-B2 |
| Application number | US-201615567187-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 26, 2016 |
| Priority date | Apr 17, 2015 |
| Publication date | Sep 15, 2020 |
| Grant date | Sep 15, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides dimeric quinacrine derivatives and related compounds and compositions, methods of treatment and syntheses. The novel compounds exhibit unexpected anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having a chemical structure which is: or a pharmaceutically acceptable salt thereof. 2. A compound according to claim 1 which is: a pharmaceutically acceptable salt thereof. 3. A compound according to claim 2 , which is: or a pharmaceutically acceptable salt thereof. 4. A method of inhibiting autophagy in a biological system in which inhibition of autophagy is desired comprising exposing said biological system to an autophagy inhibiting effective amount of a compound according to claim 1 .
Assignees
Inventors
Classifications
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title
ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines · CPC title
specific for metastasis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10774047B2 cover?
- The invention provides dimeric quinacrine derivatives and related compounds and compositions, methods of treatment and syntheses. The novel compounds exhibit unexpected anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.
- Who is the assignee on this patent?
- Univ Pennsylvania
- What technology area does this patent fall under?
- Primary CPC classification C07D219/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).